Ontology highlight
ABSTRACT: The global type 2 diabetes epidemic is a major health crisis and there is a critical need for innovative strategies to fight it. Although the microbiome plays important roles in the onset of insulin resistance (IR) and low-grade inflammation, the microbial compounds regulating these phenomena remain to be discovered. Here, we reveal that the microbiome inhibits a central kinase, eliciting immune and metabolic benefits. Through a series of in vivo experiments based on choline supplementation, blocking trimethylamine (TMA) production then administering TMA, we demonstrate that TMA decouples inflammation and IR from obesity in the context of high-fat diet (HFD) feeding. Through in vitro kinome screens, we reveal TMA specifically inhibits Interleukin-1 Receptor-associated Kinase 4 (IRAK4), a central kinase integrating signals from various toll-like receptors and cytokine receptors. TMA blunts TLR4 signalling in primary human hepatocytes and peripheral blood monocytic cells, and improves mouse survival after a lipopolysaccharide-induced septic shock. Consistent with this, genetic deletion and chemical inhibition of IRAK4 result in similar metabolic and immune improvements in HFD. In summary, TMA appears to be a key microbial compound inhibiting IRAK4 and mediating metabolic and immune effects with benefits upon HFD. Thereby we highlight the critical contribution of the microbial signalling metabolome in homeostatic regulation of host disease and the emerging role of the kinome in microbial–mammalian chemical crosstalk.
INSTRUMENT(S): Liquid Chromatography MS - positive - HILIC
PROVIDER: MTBLS12975 | MetaboLights | 2025-10-20
REPOSITORIES: MetaboLights
| Action | DRS | |||
|---|---|---|---|---|
| a_MTBLS12975_LC-MS_positive_hilic_metabolite_profiling.txt | Txt | |||
| i_Investigation.txt | Txt | |||
| m_MTBLS12975_LC-MS_positive_hilic_metabolite_profiling_v2_maf.tsv | Tabular | |||
| s_MTBLS12975.txt | Txt |
Items per page: 5 1 - 4 of 4 |